{
  "docId": "019de072-1de2-7119-a555-9ff409e7e548",
  "docSlug": "506aa41f1d83c0fffcc1a747d59c4e2b",
  "documentTitle": "Bausch Health Companies | Results Presentation Deck | 86 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 19,
  "pageCount": 86,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 18,
  "notes": "Uses a waterfall-bridge framework to explain the variance between 2021 actuals and 2022 guidance.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-1de2-7119-a555-9ff409e7e548/19",
  "deckHref": "/decks/019de072-1de2-7119-a555-9ff409e7e548",
  "deckJsonHref": "/decks/019de072-1de2-7119-a555-9ff409e7e548.json",
  "deckAnchorHref": "/decks/019de072-1de2-7119-a555-9ff409e7e548#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.75,
        "y": 0.28
      },
      "kind": "callout",
      "text": "+3% to +5% 2022 Total Company Organic Revenue Growth",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c02ab15-c255-4cbe-8ab5-892886ad4c9c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.75,
        "y": 0.55
      },
      "kind": "callout",
      "text": "+2% to +6% 2022 Total Company Adj. EBITDA (non-GAAP) Growth",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88d540e9-0ab4-480e-8d92-90df4bb9d2a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.65,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Revenue bridge from 2021 to 2022 guidance",
      "attrs": null,
      "subkind": "waterfall-bridge",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03cb0927-9f3b-42aa-95e0-8f243378e09e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.65,
        "x": 0.08,
        "y": 0.55
      },
      "kind": "chart",
      "text": "Adj. EBITDA bridge from 2021 to 2022 guidance",
      "attrs": null,
      "subkind": "waterfall-bridge",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08982c00-db07-45cd-a657-e13a28c79822",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "Guidance excludes ~$150M standalone dis-synergies (~$90M for B+L, ~$60M for Bausch Pharma and Solta Medical)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78310bba-4a94-416d-823a-799ec7ef6678",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.25,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "1. This is a non-GAAP measure... 5. See Slide 9 for disclosure...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab72abcf-53b8-48e6-a834-fb4b7cb045c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.77
      },
      "kind": "paragraph",
      "text": "Bausch Pharma -30M F/X 2%-3% Organic revenue growth; Bausch + Lomb -65M F/X 4%-5% Organic revenue growth; Solta Medical Nominal F/X 15%-18% Organic revenue growth",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aed414be-b5d0-4f76-9bed-57d57f9f576f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Full-Year Bausch Health 2022 Revenue and Adjusted EBITDA (non-GAAP)1,2,3",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18d8a3e4-ad4b-4174-9407-a92d10eb39aa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall / value bridge",
      "slug": "waterfall-bridge",
      "agent": null,
      "layer": "slide",
      "matchId": "b02693b0-ab9f-4618-b926-98c29bbab710",
      "evidence": "Adj. EBITDA bridge from 2021 to 2022 guidance",
      "confidence": 0.8
    },
    {
      "name": "Waterfall / value bridge",
      "slug": "waterfall-bridge",
      "agent": null,
      "layer": "slide",
      "matchId": "a72e8adf-45a0-48e3-845b-ba9aafa201e5",
      "evidence": "Revenue bridge from 2021 to 2022 guidance",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "waterfall-bridge",
      "slug": null,
      "matchId": "821d8d26-7e1c-4c99-832a-80ba2e29a1e0",
      "evidence": "The slide uses two waterfall charts to bridge 2021 actuals to 2022 guidance.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 31,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "44aa48cc-528a-43bd-80b7-2f1179845599",
      "evidence": "The presentation provides an overview of the company's financial results and business performance, highlighting opportunities for growth",
      "position": 1,
      "objective": "What are the opportunities for quick wins and big bets?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}